Originator: Biogen Idec

First marketed by: The Medicines Company UK Ltd.

Name of FDF: Angiox®, Angiomax®

Original FDF: Powder for reconstitution and IV injection

Other FDF: RTU solution

Mode of Action
Thrombin inhibitor. Inhibition of both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation.

Indications
Acute coronary syndromes; Heparin-induced thrombocytopenia and thrombosis syndrome; Thrombosis; Unstable angina pectoris

Patent status
Generic products are available, a RTU formulation is still patented until 2029-08-20